Patients with Ph+ CML who are non-responders to IFNand ineligible for allogeneic stem cell transplantation (SCT) have limited therapeutic options. One of these options currently under investigation is autografting. A Preliminary retrospective analysis suggests a possible survival advantage using autologous SCT. In order to design a multicenter study investigating the role of auto-grafting, a feasibility study was conducted between 1994 and 1998 on 21 patients with Ph+ CML unresponsive to IFN-( mean age 41 and disease duration 28 [5-51] months; CP: n = 18; AP: n = 3).
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Mobilization was performed using G-CSF and cyclophosphamide (CY) 7 g/m 2/ d (n = 8) or later IC (Idarubicin 8 mg/m 2 /d and cytarabine 800 m 2 /d on days 1 to 3-5; n = 13). Leukaphereses were started as soon as CD34+ cells reached 3 × 10 6 /l and continued until a minimum total of 2 × 10 6 /kg of CD34+ cells was obtained. The conditioning regimen consisted of busulfan (4 × 4 mg/kg/d) and IFNwas given as maintenance therapy post-autograft.
The target CD34+ cell-dose was achieved in 18/21 cases with 2 (1-19) leukaphereses and a total of 7.3 (2.3-318.4) ×10 6 /kg CD34+ cells was harvested. While mobilization of Ph-cells was unsuccessful with CY, in 7/11 patients with IC treatment apheresis products with only 10% (0-29%) Ph+ cells were obtained. Because of inacceptable toxicity, the cytarabine schedule was reduced from 5 (n = 4) to 4 (n = 7), and finally to 3 days (n = 2). Up to now, 16 patients were autografted. Of the 13 patients in CP, two patients are in CcyR 16 and 41 months after SCT and 5 in hematological remission. Six patients progressed and 5 died of the disease. After a median follow-up of 24 months, the OS from SCT for CML-CP patients at 3 years is 0.82 (95% CI: 0.28-0.98), and OS from diagnosis, 60 months, which compares favourably to a previous study (n = 80) where OS in patients resistant to IFN-and/or Chronic myeloid leukemia (CML) can be cured by donor marrow transplantation. The inadequate number of HLA matched donors limits the possibility of allogeneic transplantation. Autologous transplantation might be an alternative method in distinct cases. Between June 1995 and July 1998 53 patients with CML in chronic phase (43 in early and 10 in late chronic phase) were treated with myelosuppressive therapy followed by G-CSF (5-10 g/kg/day) to harvest Ph' negative PBPC.
In the 1st series 28 patients received an intensive chemotherapy regimen including idarubicine (8 mg/m 2 /day) and cytarabine (800 mg/m 2 /day) (IC) for 4 or 5 days, in a second 25 patients received the same therapy for three days only. The median duration of critical leukopenia (WBCϽ1 × 10 9 /l) was 17 days (range 4-42) in the first group versus 5 days (1-11) in the second group (p Ͻ 0,001). The side effects of chemotherapy in group 1 were severe and not tolerable. 11 patients developed severe infections. One patient died due to pneumonia. The number of CD34-positive cells was not sufficient for apheresis in 3 patients. In the 2nd group only 1 patient developed a severe infection.
PBPC were harvested by leukapheresis during the early phase of recovery from chemotherapy induced aplasia (CD34 counts of the blood had to be higher than 3 × 10 6 /l). The optimal number of CD34 + cells of the harvests was 4 × 10 6 /kg. The minimal number had to be 2 × 10 6 /kg. Ph' and bcr/abl rearrangement were detected by using cytogenetics, FISH, and colony PCR. A reduction of Ph' cells was seen in the major part of apheresis products. There were no differences between IC 5 and IC 3 days. We conclude that intensive chemotherapy (IC) followed by G-CSF can mobilize sufficient numbers of PBPC in most of effects a 3 day course of chemotherapy is preferred.
